

The Haemophilia Foundation of New Zealand Inc. (HFNZ) is a registered charity that aims to:
From the days when pain, suffering and disability were the fate of people with haemophilia, through the 1970s when some treatment became available allowing freedom and hope, through the shock and devastation associated with viral contamination of the blood supply, particularly HIV and hepatitis C, to the cautious optimism of today where state-of-the-art medication allows people with haemophilia to live full lives.
Advances in medicine over the last 50 years have meant that most people with haemophilia and other inherited bleeding disorder do now live ‘normal’ lives. Luckily, the visible impact of haemophilia is diminishing. Although not easily seen on the surface, living with haemophilia today still impacts families with newly diagnosed babies, growing children and adults with the condition in a variety of distressing and sometimes overwhelming ways.
Mission statement
To provide excellence in care, education, advocacy and support to all people in New Zealand with bleeding disorders and their family/whanau.
Through our Outreach Workers, innovative educational initiatives and camps, physical activity and support footwear programmes, and educational grants, HFNZ is able to assist people with these chronic disorders through all stages of their life. We provide the tools to give our members a voice and try to ensure they receive the best care that medicine can offer – as despite advances in genetic technology a cure remains elusive.
Today, HFNZ comprises four regions throughout the country (Northern, Midland, Central, Southern) known as Member Representative Groups (MRGs), with an Outreach Worker assigned to each. There are also two national MRGs – Piri Toto and the National Youth Committee. The National Office and administration of the Foundation is located in Christchurch. The National Council is responsible for the governance of the Foundation, on which sits the National President, two Vice-Presidents and a Treasurer, and a representative from each of the MRG's own committees. All Council positions are voluntary and decided by election at an Annual General Meeting.
HFNZ are very proud of advances and success they have achieved over the last half century. To continue to reach toward their goals, they rely largely on public donation. With the incredible generosity of the New Zealand public and the amazing support received from their Sustaining Patrons, Corporate Friends and grant applications, HFNZ look forward to many more success stories in coming years.
Role of HFNZ
Promote the personal interest, treatment, rehabilitation, lifetime care, and advancement in life, of all people with haemophilia and related genetic bleeding diseases
Hepatitis and PWID/harm reduction
11:35 – 11:40
Chair: WHO – Intro and set the scene.
11:40 – 11:55
Co-chair: EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe.
11:55 – 12:00
ID 29: Ema Pos (not yet registered)
Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation.
12:05 – 12:10
ID 152: Brian Conway (Registered in person)
Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.
12:10 – 12:15
ID 212: Jasmine West (not yet registered)
Title: From lived experience to lived expertise: a syndemic approach.
12:15 – 12:20
ID: 299 Mercy Nyakowa (Registered in person)
Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya
12:20 – 12:25
ID: 133 Nalinikanta Rajkumar (Registered in person)
Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?
12:25 – 12:30
Q&A and closing remarks
tHIS
IS
BEN’S
BIG
TEST
effective case finding strategies
Supported by Vir Biotechnology, Inc
During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.
Session Agenda
14:40 – 14:45
Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)
14:45 – 15:05
Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology
15:05 – 15:10
Final remarks and close